CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
glycyrrhizin appears in hypotheses across 3 disease domains: ALS, Epilepsy, Multiple sclerosis. Shared mediators that recur across at least two of those domains: HMGB1.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for glycyrrhizin
ALS 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| HMGB1 | ALS | 0.220 | Mid | novel signal | none |
Epilepsy 8
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| HMGB1 | epilepsy | 0.289 | High | reproduces known | none | |
| HMGB1 | drug-resistant epilepsy | 0.248 | Mid | partial evidence | none | |
| HMGB1 | drug resistance | 0.220 | Mid | reproduces known | none | |
| HMGB1 | suspected autoimmune epilepsy | 0.220 | Mid | novel signal | none | |
| HMGB1 | drug resistance | 0.220 | Mid | reproduces known | none | |
| HMGB1 | drug resistance | 0.220 | Mid | reproduces known | none | |
| HMGB1 | cognitive function | 0.220 | Mid | partial evidence | none | |
| HMGB1 | drug resistance | 0.220 | Mid | reproduces known | none |
Multiple sclerosis 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| HMGB1 | Multiple Sclerosis | 0.220 | Mid | partial evidence | none |